Viking Therapeutics, Inc. Dividend History (VKTX)
Viking Therapeutics, Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Founded in 2012, the company aims to address significant unmet medical needs by leveraging their expertise in small molecule drug development. Viking's lead product candidates include VK2809 and VK5211, with VK2809 targeting non-alcoholic fatty liver disease and hypercholesterolemia, and VK5211 being developed to promote lean body mass for patients recovering from non-elective hip fracture surgery. Headquartered in San Diego, California, Viking Therapeutics has attracted attention for its innovative approach to treating conditions with high morbidity and limited therapeutic options. As a clinical-stage company, Viking primarily relies on funding through investments and partnerships to fuel its research and development efforts.
Eli Lilly and Company
Madrigal Pharmaceuticals, Inc.
Novo Nordisk, a Danish pharmaceutical company, has seen strong growth in recent years due to its GLP-1 drugs. While the company faces increasing competition, its pipeline of obesity and diabetes treatments, including the promising semaglutide, suggests continued growth potential. However, the stock's valuation and the competitive landscape warrant caution.
The Motley Fool · Published on Fri Nov 29 2024
The article discusses three biotech stocks - CRISPR Therapeutics, Summit Therapeutics, and Viking Therapeutics - that have the potential to become much larger in the future. It highlights the key strengths and growth prospects of each company.
The Motley Fool · Published on Sat Nov 23 2024
Viking Therapeutics is a biotech company with promising weight loss and other drug candidates. Its strong financial position and upcoming clinical trial data catalysts make it an exciting investment opportunity, though investors should also be aware of its other pipeline programs.
The Motley Fool · Published on Mon Nov 18 2024